Glutamine

Glutamine

SCHEMBL411170

NC(=O)CCC([15NH2])C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 1.00
ALOX15 P16050 1/20 1.00
BLM P54132 1/20 1.00
PMP22 Q01453 1/20 1.00
GSR P00390 2/20 0.68
CYP1A2 P05177 2/20 0.68
GRM8 O00222 2/20 0.68
GRM6 O15303 2/20 0.68
GRM7 Q14831 2/20 0.68
GRM4 Q14833 2/20 0.68
GRIN2D O15399 1/20 0.68
GRIN3B O60391 1/20 0.68
GRIK1 P39086 1/20 0.68
GRM5 P41594 1/20 0.68
GRIA1 P42261 1/20 0.68
GRIA2 P42262 1/20 0.68
GRIA3 P42263 1/20 0.68
SLC1A3 P43003 1/20 0.68
SLC1A2 P43004 1/20 0.68
SLC1A1 P43005 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamine SCHEMBL31436292 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL711605 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL7452 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL411575 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL5580393 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL7453 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL994966 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL411588 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL1332116 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR
Glutamine SCHEMBL31619675 1.00 KMT2A (1.00) KMT2AALOX15BLMPMP22GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024128542-A1 CUTTING OIL COMPOSITION 와이씨켐 주식회사 2024-06-20 WO claimed
US-20210045383-A1 ORGANIC METABOLITE COMPOSITIONS AND METHODS OF USE AS MITICIDES FOR HONEY BEES NIEMCZURA PAUL (US) 2021-02-18 US claimed
WO-2019178141-A1 ORGANIC METABOLITE COMPOSITIONS AND METHODS OF USE AS MITICIDES FOR HONEY BEES NIEMCZURA PAUL (US) 2019-09-19 WO claimed
US-20040175411-A1 Method of treating influenza VANMOOR ARTHUR 2004-09-09 US claimed
US-20040176453-A1 Method of treating time-dependent changes in human subjects VANMOOR ARTHUR (US) 2004-09-09 US claimed
US-20040176454-A1 Method of treating an infection VANMOOR ARTHUR (US) 2004-09-09 US claimed
US-20040162350-A1 Method of treating a non-cancerous disease of the male prostate VANMOOR ARTHUR (US) 2004-08-19 US claimed
US-6642272-B1 Enhances the effectiveness of the human immune system by administering an amino acid amide VANMOOR ARTHUR (US) 2003-11-04 US claimed
US-20240307284-A1 EMULSION COMPOSITION AND PRODUCTION METHOD THEREOF AJINOMOTO CO., INC. (JP) 2024-09-19 US disclosed
CN-118304391-A Application of tumor neoantigen DNA vaccine and Glutamine combined anti-tumor 上海南方模式生物科技股份有限公司 2024-07-09 CN disclosed
US-20240215891-A1 Bio-Electrode Composition, Bio-Electrode, And Method For Manufacturing Bio-Electrode SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-07-04 US disclosed
US-20240215890-A1 Bio-Electrode, Bio-Electrode Composition, And Method For Manufacturing Bio-Electrode SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-07-04 US disclosed
US-20240207458-A1 TARGETED ALPHA PARTICLE THERAPY FOR SOMATOSTATIN RECEPTOR 2 POSITIVE NEUROENDOCRINE TUMORS AND METASTASES WAKE FOREST UNIVERSITY 2024-06-27 US disclosed
WO-2024126770-A1 VANADIUM COMPLEXES WITH NITROGEN AND OXYGEN DONOR ATOMS BORCHERS GMBH (DE) 2024-06-20 WO disclosed
EP-1337604-A1 REDUCING UNDESIRED POLYMERIZATION IN HYDROCARBON CRACKING PROCESSES ONDEO NALCO ENERGY SERVICES, L.P. (US) 2003-08-27 EP disclosed
WO-2002036715-A1 REDUCING UNDESIRED POLYMERIZATION IN HYDROCARBON CRACKING PROCESSES ONDEO NALCO ENERGY SERVICES, L.P. (US) 2002-05-10 WO disclosed
US-6372121-B1 ALPHA-AMINO ACIDS, ESTERS, AMIDES OR SALTS OR MERCAPTOACETIC ACID OR ESTER WHICH CONVERT CARBONYL COMPOUNDS TO STABLE WATER SOLUBLE DERIVATIVES NALCO/EXXON ENERGY CHEMICALS, L.P. 2002-04-16 US disclosed
US-6103822-A A HYDROPHILIC AND WATER BORNE POLYURETHANES FORMED FROM THE REACTION OF POLYMERIC ACID FUNCTIONAL POLYOLS WITH POLYISOCYANATES INOLEX INVESTMENT CORPORATION (US) 2000-08-15 US disclosed
EP-1013693-A1 Polymeric acid funtional polyols, polyurethanes and method for making same INOLEX INVESTMENT CORPORATION (US) 2000-06-28 EP disclosed
US-5880250-A FOR PREPARATION OF HYDROPHILIC POLYURETHANE FOAMS INOLEX INVESTMENT CORPORATION (US) 1999-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207458-A1 TARGETED ALPHA PARTICLE THERAPY FOR SOMATOSTATIN RECEPTOR 2 POSITIVE NEUROENDOCRINE TUMORS AND METASTASES SSTR2, SSTR1, SSTR5 KMT2A 2558/4885ALOX15 4206/4885BLM 4717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.